Residency · Residency · Medical Genetics Genomics
Lysosomal Storage Disorders: Enzyme Replacement and Substrate Reduction
Introduction
Lysosomal storage disorders (LSDs) represent a group of approximately 70 inherited metabolic diseases caused by deficiency of lysosomal enzymes, membrane transporters, or activator proteins. Collectively, LSDs affect approximately 1 in 5,000 to 7,500 live births. The accumulation of undegraded substrates within lysosomes leads to progressive cellular dysfunction and multi-organ disease.
Classification of Lysosomal Storage Disorders
Sphingolipidoses
The sphingolipidoses include Gaucher disease (glucocerebrosidase deficiency), which is the most common LSD overall; Fabry disease (alpha-galactosidase A deficiency); Niemann-Pick disease types A and B (sphingomyelinase deficiency); and Tay-Sachs and Sandhoff diseases (hexosaminidase deficiency).
Mucopolysaccharidoses (MPS)
The mucopolysaccharidoses encompass MPS I (Hurler/Scheie, from alpha-L-iduronidase deficiency), MPS II (Hunter, from iduronate-2-sulfatase deficiency, which is X-linked), MPS III (Sanfilippo, with multiple enzyme subtypes A through D), and MPS IV (Morquio, from galactosamine-6-sulfatase or beta-galactosidase deficiency).
Oligosaccharidoses and Glycoproteinoses
This category includes alpha-mannosidosis, fucosidosis, and the mucolipidoses.
Other Categories
Additional LSDs include Pompe disease (glycogen storage disease type II), the neuronal ceroid lipofuscinoses (CLN gene family), and cystinosis (cystinosin transporter defect).
Pathophysiology
Deficient enzyme activity leads to progressive substrate accumulation within lysosomes. Secondary pathways include inflammation, oxidative stress, and autophagy impairment. Storage material disrupts cellular architecture and triggers apoptosis. Residual enzyme activity often correlates inversely with disease severity.
Diagnostic Approach
Biochemical Testing
Diagnosis relies on enzyme activity assays performed in leukocytes, fibroblasts, or dried blood spots. Urine glycosaminoglycan (GAG) quantitation and electrophoresis screen for MPS disorders. Plasma lyso-sphingolipid biomarkers (lyso-Gb3 for Fabry, lyso-GL1 for Gaucher) provide additional diagnostic and monitoring tools.
Molecular Confirmation
Targeted gene sequencing or multi-gene LSD panels provide molecular confirmation. Genotype-phenotype correlations guide prognosis and therapy selection.
Newborn Screening
NBS for LSDs is expanding, with Pompe, Fabry, MPS I, Gaucher, and Krabbe disease increasingly included on state panels. Multiplexed enzyme assays using tandem mass spectrometry on dried blood spots enable population-level screening.
Enzyme Replacement Therapy (ERT)
Mechanism and Approved Therapies
Recombinant enzyme is administered intravenously and taken up by cells via mannose-6-phosphate receptors. Approved ERTs include imiglucerase and velaglucerase for Gaucher type 1, agalsidase alfa and beta for Fabry disease, laronidase for MPS I, idursulfase for MPS II, galsulfase for MPS VI, and alglucosidase alfa and avalglucosidase alfa for Pompe disease.
| Disorder | Deficient Enzyme | Gene | Inheritance | ERT Available | Other Therapies |
|---|---|---|---|---|---|
| Gaucher type 1 | Glucocerebrosidase | GBA1 | AR | Imiglucerase, velaglucerase | SRT (eliglustat, miglustat) |
| Fabry disease | Alpha-galactosidase A | GLA | X-linked | Agalsidase alfa/beta | Migalastat (chaperone) |
| MPS I (Hurler/Scheie) | Alpha-L-iduronidase | IDUA | AR | Laronidase | HSCT (severe form) |
| MPS II (Hunter) | Iduronate-2-sulfatase | IDS | X-linked | Idursulfase | IT-ERT investigational |
| MPS VI (Maroteaux-Lamy) | Arylsulfatase B | ARSB | AR | Galsulfase | — |
| Pompe disease | Acid alpha-glucosidase | GAA | AR | Alglucosidase alfa, avalglucosidase alfa | Gene therapy (investigational) |
| Niemann-Pick B | Sphingomyelinase | SMPD1 | AR | Olipudase alfa | — |
Limitations of ERT
ERT cannot cross the blood-brain barrier, providing limited efficacy for CNS manifestations. It requires lifelong biweekly intravenous infusions. Immunogenicity through anti-drug antibodies may reduce efficacy. Cost is substantial, typically ranging from $200,000 to over $500,000 per year.
Substrate Reduction Therapy (SRT)
Mechanism
Small-molecule inhibitors reduce biosynthesis of the accumulating substrate. Oral administration and the ability to cross the blood-brain barrier in some formulations offer advantages over ERT.
Approved Agents
Miglustat is approved for Gaucher type 1 and Niemann-Pick type C. Eliglustat, a glucosylceramide synthase inhibitor, is approved for Gaucher type 1. Venglustat is investigational for Fabry, Gaucher type 3, and GM2 gangliosidoses.
Advantages Over ERT
Oral bioavailability and potential CNS penetration represent key advantages. SRT may be used in combination with ERT for enhanced therapeutic effect.
Emerging Therapeutic Strategies
Pharmacological chaperone therapy (migalastat for amenable Fabry mutations) stabilizes misfolded enzyme to improve its trafficking to lysosomes. Gene therapy approaches (AAV-mediated and lentiviral) are in clinical trials for multiple LSDs. Hematopoietic stem cell transplantation remains the standard of care for Hurler syndrome (MPS IH) and some leukodystrophies, providing both enzyme delivery and CNS penetration through donor-derived microglia. Intrathecal ERT for direct CNS delivery is under investigation for neuronopathic forms.
Monitoring and Multidisciplinary Care
Regular assessment includes organ volume monitoring (liver, spleen), skeletal disease evaluation, and biomarker tracking. Cardiac surveillance is essential in Fabry and Pompe disease. Neurodevelopmental monitoring is critical in MPS III and neuronal ceroid lipofuscinoses. Multidisciplinary teams including metabolic specialists, geneticists, physical therapists, and social workers coordinate comprehensive care.
Clinical Pearls
Early diagnosis and treatment initiation are critical because irreversible organ damage occurs before clinical symptoms in many LSDs. ERT is effective for visceral and hematologic manifestations but does not adequately treat CNS or skeletal disease. Newborn screening is expanding access to presymptomatic diagnosis but raises challenges around late-onset phenotypes and variants of uncertain significance. Combination and next-generation therapies (gene therapy, chaperones) offer hope for addressing current treatment gaps.
References
- Platt FM, d'Azzo A, Davidson BL, et al. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27.
- Kishnani PS, Beckemeyer AA, Gruskin DJ. Enzyme replacement therapy and emerging therapies for lysosomal storage diseases. Annu Rev Genomics Hum Genet. 2024;25:255-282.
- Pastores GM, Hughes DA. Gaucher disease. In: GeneReviews. University of Washington, Seattle; updated 2023.
- ClinicalTrials.gov. Gene therapy trials for lysosomal storage disorders. Accessed 2026.